Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Catumaxomab in ovarian cancer with malignant ascites
NCT00326885Phase 2Completed
- Sponsor
- Neovii Pharmaceuticals
- Start
- Jun 2006
- Primary completion
- Dec 2009
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of catumaxomab in malignant ascites, sponsored by Neovii Pharmaceuticals. Started Jun 2006; status: completed.
02
Drugs
catumaxomab
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NCT00326885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00326885.